Skip to content

CG Oncology CGON Total Liabilities

Total Liabilities at other companies

Pfizer logo
PfizerPFE
$3.41B-97.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$119.71B+3.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.52B+69.5%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$295.31M+356%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$104.42M+51.8%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$101.92M+158%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%
Enterprise value$5.36B+212%
P/S1,062.4×-1,596×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's total liabilities?
CG Oncology (CGON) reported total liabilities of $43.48M in Q1 2026.
How has CG Oncology's total liabilities changed year-over-year?
CG Oncology's total liabilities increased by 85.6% year-over-year, from $23.42M to $43.48M.
What is the long-term trend for CG Oncology's total liabilities?
Over 2 years (2023 to 2025), CG Oncology's total liabilities has grown at a 63.9% compound annual growth rate (CAGR), from $14.51M to $38.99M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.